Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms

International Journal of Impotence Research

Volumn 10, Issue 4, 1998, Pages 215-223

  Traish, A ^a   Gupta, S ^a   Gallant, C ^a   Huang, Y H ^a   Goldstein, I ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Doctors Office Building   (United States)

Author keywords

Corpus cavernosum smooth muscle; Erectile dysfunction; Penile erection; Phentolamine mesylate; adrenergic receptors

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; ENDOTHELIN; IODINE 125; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; NORADRENALIN; OXYMETAZOLINE; PHENTOLAMINE MESYLATE; PHENYLEPHRINE; POTASSIUM CHLORIDE; PRAZOSIN; RAUWOLSCINE; TRITIUM;

ADRENERGIC SYSTEM; ANIMAL TISSUE; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG BINDING; DRUG MECHANISM; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; RABBIT; RADIOASSAY; SMOOTH MUSCLE RELAXATION; VASCULAR ENDOTHELIUM;

EID: 0032435191     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900351     Document Type: Article

References (16)

1. Krane RJ, Goldstein I, Saenz de Tejada I. Medical progress: Impotence. N Engl J Med 1989; 321: 1648-1659.
2. Zorgniotti A. Pre-IND Meeting Documents of Gamogen, Inc., Reference to Bruce F. Mackler letter of March 8, 1994.
3. Gwinup G. Oral phentolamine in nonspecific erectile insufficiency. Ann Int Med 1988; 109: 162-163.
4. Wagner G, Lacy S, Lewis R, Zorgniotti A. Buccal phentolamine - A pilot trial for male erectile dysfunction at three separate clinics. Int J Impot Res 1994; 6 Suppl 1: D78.
5. Porst H et al. Oral phentolamine (Vasomax) in erectile dysfunction - Results of German multicenter study in 177 patients. Int J Impot Res 1996; 8: 117.
6. Becker AJ et al. Double blind study on oral phentolamine as treatment for erectile dysfunction. J Urol 1997; 157; 202.
7. Goldstein I and the Vasomax Study Group. Efficacy and safety of oral phentolamine (Vasomax) for the treatment of minimal erectile dysfunction. J Urol 1998; 159; 240.
8. Becker AJ et al. Oral phentolamine as treatment for erectile dysfunction. J Urol 1998; 159; 1214-1216.
9. Harris Laboratories Ltd. Study No. 16800. A Single-Center, Seven-Period, Rising-Dose, Tolerance Study of Phentolamine Mesylate Suppositories. November 2, 1994.
10. Hoffman BB. Adrenoceptor blocking drugs. In: Katzung BG, ed. Basic and Clinical Pharmacology. Appleton and Lang: Norwalk, CT, 1992, pp 132-146.
11. Saenz de Tejada I et al. Regulation of adrenergic activity in penile corpus cavernosum. J Urol 1989; 142; 1117-1121.
12. Saenz de Tejada I, Carson MP, Goldstein I, Traish AM. Endothelin synthesis, activity and receptor types in the human penis. Am J Physiol 1991; 261; H1078-H1085.
13. Traish AM et al. A heterogenous population of alpha-1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. J Urol 1994; 153; 222-227.
14. Traish AM, Palmer MS, Goldstein I, Moreland RB. Expression of functional muscarinic acetylcholine receptor subtypes in human corpus cavernosum and in cultured smooth muscle cells in culture. Receptors 1995; 5; 159-167.
15. Rembold CM. Electromechanical and pharmacomechanical coupling. In: Barany M, ed. Biochemistry of Smooth Muscle Contraction. Academic Press: San Diego, 1996, pp 227-239.
16. Moreland RB, Goldstein I, Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci: Pharmacol Lett 1998; 62: 309-318.